Rift Valley Fever Virus DIVA vaccine | BCH-LMO-SCBD-115616 | Living Modified Organism | Biosafety Clearing-House
BCH Biosafety Clearing-House
CBD / BCH / Search / Record

Loading...
  |  

Living Modified Organism (LMO)

Decisions on the LMO Risk Assessments  
published: 18 Jun 2020 last updated: 27 Jul 2020
Living Modified Organism identity
The image below identifies the LMO through its unique identifier, trade name and a link to this page of the BCH. Click on it to download a larger image on your computer. For help on how to use it go to the LMO quick-links page.
Rift Valley Fever Virus DIVA vaccine
EN
ChAdOx1-Gn-Gc
  • - Person: Dr. George Warimwe | BCH-CON-SCBD-115615-2
    Person
    Dr. George Warimwe
    Principal Scientist,
    Nairobi,
    , Kenya
    Phone: +1865617622,
    Fax: +1865617608,
    Email: gwarimwe@kemri-wellcome.org,
    Website:
    Related Organization
    International Livestock Research Institute (ILRI) /The Jenner Institute, University of Oxford, United Kingdom ()
    Academic or research institute
    Nairobi,
    , Kenya
    Phone: +1865617622,
    Fax: +1865617608,
    Email: gwarimwe@kemri-wellcome.org,
    Website:
ChAdOx1-GnGc is a DIVA (differentiating infected from vaccinated animals) vaccine composed of a replication-deficient simian adenovirus vector expressing Rift valley fever phlebovirus envelope glycoproteins (amino-terminus and carboxy-terminus glycoproteins). Together, the glycoproteins form virus-like particles, which are expected to elicit a strong immune response to viral challenges in livestock, such as sheep, goats, cattle and dromedary camels. The disease is characterized by high rates of mortality in newborn animals and abortions in those that are pregnant. The modified adenovirus is not expected to replicate within the animal due to the deletion of gene E1, which is responsible for replication.
EN
The term “Recipient organism” refers to an organism (either already modified or non-modified) that was subjected to genetic modification, whereas “Parental organisms” refers to those that were involved in cross breeding or cell fusion.
ChAdOx1 (Chimpanzee Adenovirus Oxford 1) is a replication-deficient vaccine vector derived from Chimpanzee adenovirus Y25 and contains a deletion of the gene responsible for replication, E1.
EN
Characteristics of the modification process
ChAdOx1
EN
  • Direct DNA transfer
Some of these genetic elements may be present as fragments or truncated forms. Please see notes below, where applicable.
  • BCH-GENE-SCBD-115612-2 Glycoprotein Gn - Rift Valley fever phlebovirus - RVFV
    Production of medical or pharmaceutical compounds (human or animal) - Vaccines, Antibodies and antigens
  • BCH-GENE-SCBD-115609-1 Major immediate early promoter containing intron A - Human betaherpesvirus 5 - Human cytomegalovirus, HCMV, HHV-5
  • BCH-GENE-SCBD-115614-1 Human tissue plasminogen activator leader sequence - Homo sapiens - HUMAN
  • BCH-GENE-SCBD-115580-1 Bovine growth hormone terminator - Bos taurus - Cow, Cattle, Bull, Auroch, Oxen, Bullocks
  • BCH-GENE-SCBD-115613-1 Glycoprotein Gc - Rift Valley fever phlebovirus - RVFV
    Production of medical or pharmaceutical compounds (human or animal) - Vaccines, Antibodies and antigens
Gene expression
Transcription of the Rift valley fever phlebovirus glycoproteins Gn and Gc are under control of the Human cytomegalovirus major immediate-early promoter and the Bos taurus bovine growth hormone terminator. A human tissue plasminogen activator leader sequence is also included to enhance the expression of the glycoproteins.

Note:
- The Human cytomegalovirus immediate early promoter contains intron A, which enhances expression of the downstream elements by promoting strong transcription.
- The Human cytomegalovirus immediate early promoter contains the following portions: Regulatory sequence (437 bp); Enhancer (481 bp); Promoter (62 bp); Exon A (120 bp); and Intron A (824 bp) (total size 1924 bp).
- The Rift valley fever virus glycoproteins Gn and Gc were isolated from the M segment of the viral genome (base pairs: 411 to 3614)

Please note: Genetic element sizes have not been confirmed
EN
LMO characteristics
EN
  • Vaccine
Detection method(s)
EN
Records referencing this document Show in search
Record type Field Record(s)
Country's Decision or any other Communication Living modified organism(s) 1
Risk Assessment generated by a regulatory process Living modified organism(s) 1

Quick links

About the BCH About the Cartagena Protocol Supplementary Protocol

Sign in Search records Submit records
National Report Analyzer

Forums BCH Announcements

Need help?

Knowledge Base FAQs Training Materials Training Site

Contact us at: bch@cbd.int
BCH Biosafety Clearing-House
Subscribe to e-mail notifications
Subscribe to our newsletter